EGFR and hepatocellular carcinoma: In addition, erlotinib is a monoclonal antibody that primarily targets EGFR, and a meta-analysis published in 2019 found that bevacizumab in combination with erlotinib is effective and safe for second-line treatment of advanced HCC (He et al., 2019).